Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Primary Pulmonary Lymphoepithelioid Carcinoma
NCT03709953Phase 2Unknown
- Sponsor
- Guangzhou Institute of Respiratory Health
- Start
- Oct 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in pulmonary lymphoepithelioma-like carcinoma (PLELC), sponsored by Guangzhou Institute of Respiratory Health. Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
pulmonary lymphoepithelioma-like carcinoma (PLELC)
Beyond the preview
Go deeper on NCT03709953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03709953.